Buscar en
Clínica e Investigación en Arteriosclerosis
Toda la web
Inicio Clínica e Investigación en Arteriosclerosis Efectos hipoglucemiantes de las resinas de intercambio. Del secuestro de los ác...
Información de la revista
Vol. 23. Núm. S2.
Nuevos horizontes en el tratamiento global del riesgo cardiovascular del paciente diabético
Páginas 3-8 (Septiembre 2011)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 23. Núm. S2.
Nuevos horizontes en el tratamiento global del riesgo cardiovascular del paciente diabético
Páginas 3-8 (Septiembre 2011)
Acceso a texto completo
Efectos hipoglucemiantes de las resinas de intercambio. Del secuestro de los ácidos biliares a la activación del metabolismo de la glucosa
Hypoglycemic effects of anion exchange resins. From bile acid sequestering to glucose metabolism activation
Visitas
2412
Josep Franch Nadal
EAP Raval Sud-ICS Barcelona, Unitat de Suport a la Recerca de Barcelona-IDIAP, redGDPS, CAP Drassanes, Barcelona, España
Este artículo ha recibido
Información del artículo
Resumen
Bibliografía
Descargar PDF
Estadísticas
Resumen

La diabetes y la dislipemia se hallan íntimamente relacionadas, tanto por su frecuente aparición conjunta como porque, cuando eso ocurre, se potencia el riesgo cardiovascular de ese paciente. El objetivo del tratamiento de la diabetes y sus factores asociados es minimizar el exceso de riesgo; por ello, cuando se da un tratamiento específico para controlar alguno de los factores de riesgo (hiperglucemia, presión arterial o dislipemia) es deseable que no empeore los otros factores de riesgo. En este sentido, algunos fármacos como las resinas de intercambio han demostrado, además de reducir los lípidos, ser beneficiosos para el metabolismo de la glucosa, reduciendo los valores de HbA1c en aproximadamente un 0,7%. Los mecanismos por los que se produce este efecto aún no son plenamente conocidos, pero parece ser que intervienen en la activación de receptores nucleares como el receptor farnesoide X y el receptor TGR5.

Palabras clave:
Diabetes
Control metabólico
Dislipemia
Resinas de intercambio
Abstract

Diabetes and dyslipidemia are intimately related due to their frequent association, which also increases cardiovascular risk. The treatment of diabetes and its associated factors aims to minimize excess risk and therefore specific treatments to control a particular risk factor (hyperglycemia, hypertension or dyslipidemia) should not aggravate other risk factors. In this context, some drugs, such as anion exchange resins, not only lower lipid levels but also improve glucose metabolism, reducing HbA1c levels by approximately 0.7%. The mechanisms through which this effect is produced are not yet fully known but seem to involve activation of nuclear receptors such as the farnesoid X receptor and the TGR5 receptor.

Keywords:
Diabetes
Metabolic control
Dyslipidemia
Anion exchange resins
El Texto completo está disponible en PDF
Bibliografía
[1.]
R.P. Donahue, T.J. Orchard.
Diabetes mellitus and macrovascular complications.
Diabetes Care, 15 (1992), pp. 1141-1152
[2.]
W.B. Kannel, D.L. McGee.
Diabetes and cardiovascular disease. The Framingham Study.
JAMA, 241 (1979), pp. 2035-2038
[3.]
J. Stamler, O. Vaccaro, J.D. Neaton, D. Wentworth.
Diabetes, other risk factors and 12-yr cardiovascular mortality in men screened in the Multiple Risk Factor Intervention Trial.
Diabetes Care, 16 (1993), pp. 434-444
[4.]
P. Gaede, H. Lund-Andersen, H.H. Parving, O. Pedersen.
Effect of a multifactorial intervention on mortality in type 2 diabetes.
N Engl J Med, 358 (2008), pp. 580-591
[5.]
R.J. Stevens, V. Kothari, A.I. Adler, I.M. Stratton.
United Kingdom Prospective Diabetes Study (UKPDS) Group. The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56).
Clin Sci (Lond), 101 (2001), pp. 671-679
[6.]
P. Gaede, O. Pederson.
Intensive integrated therapy of type 2 diabetes. Implications for long-term prognosis.
Diabetes, 53 (2004), pp. S39-S47
[7.]
R.D. Siegel, A. Cupples, E.J. Schaefer, P.W.F. Wilson.
Lipoproteins, apolipo-proteins and low-density lipoprotein size among diabetics in the Framingham Offspring study.
Metabolism, 45 (1996), pp. 1267-1272
[8.]
J.D. Brunzell, M. Davidson, C.D. Furberg, R.B. Goldberg, B.V. Howard, J.H. Stein, et al.
Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation.
Diabetes Care, 31 (2008), pp. 811-822
[9.]
American Diabetes Association.
Standards of Medical Care in Diabetes.
Diabetes Care, 34 (2011), pp. s11-s61
[10.]
L. Masana, N. Plana.
Actualización de las tablas de planificación terapéutica de la hipercolesterolemia.
Med Clin (Barc), 135 (2010), pp. 120-123
[11.]
W. Insull Jr.
Clinical utility of bile acid sequestrants in the treatment of dyslipidemia: a scientific review.
[12.]
H.E. Bays, R.B. Goldberg.
The Forgotten Bile Acid Sequestrants: Is Now a Good Time to Remember?.
Am J Ther, 14 (2007), pp. 567-580
[13.]
D.S.H. Bell, J.H. O’Kefee.
Rediscovering bile acid sequestrants.
Diabetes, Obesity and Metabolism, 11 (2009), pp. 1114-1121
[14.]
H.W. Rodbard, P.S. Jellinger, J.A. Davidson, D. Einhorn, A.J. Garber, G. Grunberger, et al.
Statement by an American Association of Clinical Endocrinologists /American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control.
Endocr Pract, 15 (2009), pp. 540-559
[15.]
M. Kobayashi, H. Ikegami, T. Fujisawa, K. Nojima, Y. Kawabata, S. Noso, et al.
Prevention and treatment of obesity, insulin resistance, and diabetes by bile acid-binding resin.
Diabetes, 56 (2007), pp. 239-247
[16.]
B. Steals, Y. Handelsman, V. Fonseca.
Bile acid sequestrants for lipid and glucose control.
Curr Diab Rep, 10 (2010), pp. 70-77
[17.]
B. Steals.
A review of bile acid sequestrants: potential mechanism(s) for glucose-lowering effects in type 2 diabetes mellitus.
Postgraduate Medicine, 121 (2009), pp. 25-30
[18.]
B. Steals, V. Fonseca.
Bile Acids and Metabolic Regulation. Mechanisms and clinical responses to bile acid sequestration.
Diabetes Care, 32 (2009), pp. s237-s245
[19.]
P. Guzelian, J.L. Boyer.
Glucose reabsorption from bile: evidence for a biliohepatic circulation.
J Clin Invest, 53 (1974), pp. 526-535
[20.]
J.Y. Chiang, R. Kimmel, C. Weinberger, D. Stroup.
Farnesoid X receptor responds to bile acids and represses cholesterol 7alpha-hydroxylase gene (CYP7A1) transcription.
J Biol Chem, 275 (2000), pp. 10918-10924
[21.]
D.J. Freeman, J. Norrie, N. Sattar, R.D. Neely, S.M. Cobbe, I. Ford, et al.
Pravastatin and the developement of diabetes mellitus. Evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study.
Circulation, 103 (2001), pp. 357-362
[22.]
P.M. Ridker, E. Danielson, F. Fonseca, J. Genest, A. Gotto, J. Kastelein, et al.
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.
N Engl J Med, 359 (2008), pp. 2195-2207
[23.]
N. Sattar, D. Preiss, H.M. Murray, P. Welsh, B.M. Buckley, A. De Craen, et al.
Statins and risk of incident diabetes: a collaborative metaanalysis of randomised statin trials.
[24.]
D. Preiss, S. Rao, P. Ewlsh, S. Murphy, J. Ho, D. DeMicco, et al.
Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy. A Meta-analysis.
JAMA, 305 (2011), pp. 2556-2564
[25.]
A. Tenenbaum, M. Motro, E.Z. Fisman, E. Schwammenthal, Y. Adler, I. Goldenberg, et al.
Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease.
Circulation, 109 (2004), pp. 2197-2202
[26.]
S.J. Yang, J.M. Choi, L. Kim, B.J. Kim, J.H. Sohn, W.J. Kim, et al.
Chronic administration of ezetimibe increases active glucagonlike peptide-1 and improves glycemic control and pancreatic beta cell mass in a rat model of type 2 diabetes.
Biochem Biophys Res Commun, 407 (2011), pp. 153-157
[27.]
A. Garg, S.M. Grundy.
Cholestyramine therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. A short-term, doubleblind, crossover trial.
Ann Intern Med, 121 (1994), pp. 416-422
[28.]
T. Yamakawa, T. Takano, H. Utsunomiya, K. Kadonosono, A. Okamura.
Effect of colestimide therapy for glycemic control in type 2 diabetes mellitus with hypercholesterolemia.
Endocr J, 54 (2007), pp. 53-58
[29.]
F.J. Zieve, M.F. Kalin, S.L. Schwartz, M.R. Jones, W.L. Bailey.
Results of the glucose-lowering effect of WelChol study GLOWS: a randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes.
[30.]
H.E. Bays, R.B. Goldberg, K. Truitt, et al.
Addition of colesevelam HCl to patients with type 2 diabetes mellitus inadequately controlled on a metformin-based therapy improves glycemic control.
Poster presentation AACE. 16th Annual Meeting and Clinical Congress,
[31.]
R.B. Goldberg, K. Truitt.
Colesevelam HCl improves glycemic control in type 2 diabetes mellitus subjects managed with insulin therapy.
Poster presentation. American Heart Association Annual Meeting,
[32.]
V. Fonseca, J. Rosenstock, A. Wang, K. Truitt, M. Jones.
Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy.
Diabetes Care, 31 (2008), pp. 1479-1484
Copyright © 2011. Sociedad Española de Arteriosclerosis y Elsevier España S.L.
Opciones de artículo
Herramientas
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos